BE2020C517I2 - - Google Patents

Download PDF

Info

Publication number
BE2020C517I2
BE2020C517I2 BE2020C517C BE2020C517C BE2020C517I2 BE 2020C517 I2 BE2020C517 I2 BE 2020C517I2 BE 2020C517 C BE2020C517 C BE 2020C517C BE 2020C517 C BE2020C517 C BE 2020C517C BE 2020C517 I2 BE2020C517 I2 BE 2020C517I2
Authority
BE
Belgium
Application number
BE2020C517C
Other languages
Dutch (nl)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32607514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2020C517(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BE2020C517I2 publication Critical patent/BE2020C517I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Compositions Of Oxide Ceramics (AREA)
BE2020C517C 2004-05-18 2020-06-11 BE2020C517I2 (en, 2012)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0411056.5A GB0411056D0 (en) 2004-05-18 2004-05-18 Organic compounds

Publications (1)

Publication Number Publication Date
BE2020C517I2 true BE2020C517I2 (en, 2012) 2024-08-08

Family

ID=32607514

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2020C517C BE2020C517I2 (en, 2012) 2004-05-18 2020-06-11

Country Status (33)

Country Link
US (6) US20080267886A1 (en, 2012)
EP (3) EP3603634B1 (en, 2012)
JP (2) JP5567252B2 (en, 2012)
KR (2) KR20130018429A (en, 2012)
CN (1) CN1953745A (en, 2012)
AT (1) ATE521348T1 (en, 2012)
AU (1) AU2005244439C1 (en, 2012)
BE (1) BE2020C517I2 (en, 2012)
BR (1) BRPI0511327B8 (en, 2012)
CA (1) CA2563302C (en, 2012)
CY (4) CY1112086T1 (en, 2012)
DK (2) DK2228064T3 (en, 2012)
EC (1) ECSP066950A (en, 2012)
ES (2) ES2775979T3 (en, 2012)
FR (1) FR20C1018I2 (en, 2012)
GB (1) GB0411056D0 (en, 2012)
HU (3) HUE048936T2 (en, 2012)
IL (1) IL179013A (en, 2012)
LT (3) LT2228064T (en, 2012)
LU (1) LUC00155I2 (en, 2012)
MA (1) MA28598B1 (en, 2012)
MX (1) MXPA06013382A (en, 2012)
NO (2) NO334760B1 (en, 2012)
NZ (1) NZ550369A (en, 2012)
PL (2) PL2228064T3 (en, 2012)
PT (2) PT1755590E (en, 2012)
RU (1) RU2388465C2 (en, 2012)
SE (1) SE1755590T5 (en, 2012)
SG (1) SG153836A1 (en, 2012)
SI (2) SI2228064T1 (en, 2012)
TN (1) TNSN06377A1 (en, 2012)
WO (1) WO2005110402A1 (en, 2012)
ZA (1) ZA200608123B (en, 2012)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CA2595791C (en) * 2005-03-16 2013-10-08 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
CA2607391A1 (en) * 2005-04-23 2006-11-02 Boehringer Ingelheim International Gmbh Combination of medicaments to be inhaled, containing a betamimetic agent and a steroid in addition to an anticholinergic agent
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0523656D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
EP1878722A1 (en) * 2006-07-13 2008-01-16 Novartis AG Quinolinone derivatives and their pharmaceutical compositions
MY150468A (en) * 2006-06-30 2014-01-30 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
EP1938822A1 (en) * 2006-12-21 2008-07-02 Novartis AG Combination therapy for the treatment of airways disease
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
JP5873013B2 (ja) 2009-05-29 2016-03-01 パール セラピューティクス，インコーポレイテッド ２つ以上の活性剤を呼吸器送達するための組成物、方法および系
CA2764867C (en) * 2009-06-09 2016-05-17 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
MX2012006878A (es) 2009-12-23 2012-07-04 Chiesi Farma Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc).
CA2785349C (en) 2009-12-23 2018-07-03 Chiesi Farmaceutici S.P.A. Combination therapy for copd
RU2018115685A (ru) * 2011-02-17 2019-03-05 Сипла Лимитед Фармацевтическая композиция
KR101317924B1 (ko) * 2011-05-17 2013-10-16 김동진 글리코피롤레이트의 합성방법 및 이 활성성분을 함유하는 약학적 조성물의 제조방법
EA201590019A1 (ru) 2012-07-05 2015-09-30 Арвен Айлак Санайи Ве Тиджарет А.С. Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы
WO2014007767A1 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose and a ternary component
KR101460694B1 (ko) * 2012-09-07 2014-11-11 성광제약주식회사 글리코피롤레이트의 신규 합성방법 및 이 활성성분을 함유하는 약학적 조성물
CN103784401A (zh) * 2012-10-29 2014-05-14 北京市丰硕维康技术开发有限责任公司 一种治疗呼吸道疾病的溶液型定量吸入气雾剂及制备方法
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
ES2699257T3 (es) 2013-02-28 2019-02-08 Dermira Inc Sales de glicopirrolato
MX361286B (es) 2013-03-15 2018-12-03 Pearl Therapeutics Inc Métodos y sistemas para el acondicionamiento de materiales cristalinos de partículas.
MX368835B (es) 2013-12-30 2019-10-18 Chiesi Farm Spa Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol.
TN2017000077A1 (en) 2014-09-09 2018-07-04 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
WO2017178966A1 (en) * 2016-04-11 2017-10-19 Suven Life Sciences Limited Topical spray formulation of glycopyrrolate
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
WO2020217143A1 (en) * 2019-04-23 2020-10-29 Glenmark Pharmaceutical Limited Inhalable dry powder composition comprising gly copyrronium, indacaterol and fluticasone
WO2020247376A1 (en) * 2019-06-03 2020-12-10 Cai Gu Huang Inhalable formulation of a solution containing indacaterol maleate and glycopyrronium bromide
WO2021110239A1 (en) 2019-12-02 2021-06-10 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers

Family Cites Families (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
JPS6235216A (ja) 1985-08-09 1987-02-16 Noritoshi Nakabachi 不均質物質層の層厚非破壊測定方法および装置
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
US5416013A (en) 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
US5451700A (en) 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
CA2071674C (en) 1991-06-21 2003-08-19 Kevin T. Chapman Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
ATE257517T1 (de) 1991-08-30 2004-01-15 Vertex Pharma Interleukin 1-beta protease und ihre inhibitoren
EP0547699A1 (en) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
AU3479593A (en) 1992-01-31 1993-09-01 Merck & Co., Inc. Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
ATE169224T1 (de) 1992-02-21 1998-08-15 Merck & Co Inc Peptidylderivate und inhibitoren des interleukin- 1-g(b)-konvertierenden enzyms
WO1993018007A1 (en) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Novel carbostyril derivative
SK279958B6 (sk) 1992-04-02 1999-06-11 Smithkline Beecham Corporation Zlúčeniny s protialergickým a protizápalovým účink
US5605923A (en) 1992-04-02 1997-02-25 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
WO1993019750A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic or inflammatory diseases
EP0648128A4 (en) 1992-06-24 1995-07-26 Merck & Co Inc DNA ENCODING THE INTERLEUKIN PRECURSOR 1-g (b) CONVERSION ENZYME.
DE69319432T2 (de) 1992-07-31 1998-10-29 Pfizer Peptide aus Derivaten der 4-Amino-2.2.-Difluoro-3-Oxo-1.6-Hexandisäure als Wirkstoffe gegen Entzündungen
US5395958A (en) 1992-09-30 1995-03-07 Mitsubishi Kasei Corporation Cyclopropene derivatives
CA2109646C (en) 1992-11-24 2000-03-07 Gaston O. Daumy Para-nitroanilide peptides
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5656600A (en) 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5411985A (en) 1993-05-17 1995-05-02 Merck & Co., Inc. Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme
JPH0789951A (ja) 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
ES2122145T3 (es) 1993-06-04 1998-12-16 Vertex Pharma Fosfiniloximetil-cetonas peptidicas como inhibidores de la enzima convertida de la interleuquina-1 beta.
EP0628550B1 (en) 1993-06-08 1998-02-25 Sanofi Pyridazines as interleukin-1beta converting enzyme inhibitors
DE4326959C2 (de) 1993-08-12 1995-07-06 Henkel Kgaa Verwendung von Fettsäure-N-alkylpolyhydroxyalkylamiden
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
EP0995457B1 (de) 1995-12-07 2004-03-10 Jago Research Ag Mundstück für einen Inhalator zur mehrfachen dosisweisen Abgabe eines pharmakologischen Trockenpulvers
US5843904A (en) 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
WO1998010778A1 (en) 1996-09-12 1998-03-19 Idun Pharmaceuticals, Inc. INHIBITION OF APOPTOSIS USING INTERLEUKIN-1β-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS
NZ334605A (en) 1996-09-12 2000-08-25 Idun Pharmaceuticals Inc C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases and for treatments of inflammatory, autoimmune, neurodegenerative disorders and in the prevention of ischemic injury
JP2000501428A (ja) 1996-09-12 2000-02-08 アイドゥン ファーマシューティカルズ，インコーポレイテッド 酵素のｉｃｅ／ｃｅｄ−３プロテアーゼファミリーを阻害する新規な三環式化合物
US6610683B2 (en) 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
EP1369414A1 (de) * 1996-11-11 2003-12-10 Christian R. Noe Enantiomerenreine Arylcycloalkyl-Hydroxycarbonsäureester, Verfahren zu ihrer Herstellung und ihre Verwendung als Muskarinrezeptor-Modulatoren
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CA2282845A1 (en) 1997-03-18 1998-09-24 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6054487A (en) 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
AR016384A1 (es) 1997-07-30 2001-07-04 Smithkline Beecham Corp Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta.
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723566D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
PE20000270A1 (es) 1998-02-14 2000-05-20 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
KR100928878B1 (ko) 1998-03-19 2009-11-30 버텍스 파마슈티칼스 인코포레이티드 카스파제의 억제제
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
AR019322A1 (es) 1998-06-18 2002-02-13 Smithkline Beecham Corp Derivados de sulfonilo sustituido por heterociclo-etanodionanilina sustituida por heterociclo, composicion farmaceutica que los contiene y su uso para lamanufactura de un medicamento
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813565D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
ATE246701T1 (de) 1998-06-23 2003-08-15 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivate
EP1098923B1 (en) 1998-06-30 2004-11-17 Dow Global Technologies Inc. Polymer polyols and a process for the production thereof
ATE283033T1 (de) 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
BR9914526A (pt) 1998-10-16 2001-07-03 Pfizer Derivados de adenina
NZ511527A (en) 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
GB9902689D0 (en) 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
ES2260043T3 (es) 1999-08-21 2006-11-01 Altana Pharma Ag Combinacion sinergica de roflumilast y salmeterol.
AU7127600A (en) 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US6369115B1 (en) 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
KR20020093083A (ko) 2000-04-27 2002-12-12 베링거 잉겔하임 파르마 카게 신규한 완효성 베타모사체, 이의 제조방법 및 약제로서의이의 용도
TWI227240B (en) 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
GB0015727D0 (en) 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
AU6610001A (en) 2000-06-27 2002-01-08 S A L V A T Lab Sa Carbamates derived from arylalkylamines
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
ATE380194T1 (de) 2000-08-05 2007-12-15 Glaxo Group Ltd 6.alpha.,9.alpha.-difluoro-17.alpha.-(2-
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
US20020193392A1 (en) 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
ATE305468T1 (de) 2000-12-22 2005-10-15 Almirall Prodesfarma Ag Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
PT1353919E (pt) 2000-12-28 2006-11-30 Almirall Prodesfarma Ag Novos derivados de quinuclidina e composições medicinais contendo os mesmos
US20020179087A1 (en) 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ　グループ　リミテッド βアドレナリン受容体のアゴニスト
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
ES2296923T3 (es) 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
EP1381602A1 (en) 2001-04-19 2004-01-21 Vertex Pharmaceuticals Incorporated Heterocyclyldicarbamides as caspase inhibitors
DE60229372D1 (de) 2001-04-30 2008-11-27 Glaxo Group Ltd Antiphlogistische 7.beta.-carbothioate esterderivate von androstan mit einer 17.alpha.-zyklischen estergruppe
BR0209986A (pt) 2001-05-25 2004-04-06 Pfizer Agonista de a2a em combinação com um agente anticolinérgico, para o tratamento de doenças obstrutivas das vias respiratórias
EP1395604B1 (en) 2001-06-12 2008-06-25 Glaxo Group Limited Novel anti inflammatory 17.alpha.-heterocyclic-esters of 17.beta.-carbothioate androstane derivatives
EP1578910A4 (en) 2001-06-21 2008-06-04 Verenium Corp NITRILASES
ITMI20010357U1 (it) 2001-06-28 2002-12-30 Plastiape Spa Dispositivo inalatore
ES2316599T3 (es) 2001-09-14 2009-04-16 Glaxo Group Limited Derivados de fenetanolamina para el tratamiento de enfermedades respiratorias.
IL160896A0 (en) 2001-10-17 2004-08-31 Ucb Sa Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
DK1444233T3 (da) 2001-11-09 2011-10-17 Gilead Palo Alto Inc A2B-adenosinreceptorantagonister
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003048181A1 (en) 2001-12-01 2003-06-12 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
PL211250B1 (pl) 2001-12-20 2012-04-30 Chiesi Farma Spa Pochodne karbaminianu 1-alkilo-1-azoniabicyklo [2.2.2] oktanu, jej zastosowania, kompozycja farmaceutyczna zawierająca ten związek oraz związek pośredni
WO2003072592A1 (en) 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003062259A2 (en) 2002-01-21 2003-07-31 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
US6933410B2 (en) 2002-03-08 2005-08-23 Novartis Ag Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine
EP1490062B1 (en) 2002-03-26 2007-12-19 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CA2477764A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
AU2003234716A1 (en) 2002-04-10 2003-10-27 Joel M. Linden Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
JP4570878B2 (ja) 2002-04-11 2010-10-27 メルク・シャープ・エンド・ドーム・コーポレイション 選択的糖質コルチコイド受容体モジュレーターとしての１Ｈ−ベンゾ［ｆ］インダゾール−５−イル誘導体
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
DE60318193T2 (de) 2002-04-25 2008-12-04 Glaxo Group Ltd., Greenford Phenethanolaminderivate
JP2005527618A (ja) 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト
ES2201907B1 (es) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
DE10227269A1 (de) 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
WO2004000814A1 (en) 2002-06-25 2003-12-31 Merck Frosst Canada & Co. 8-(biaryl) quinoline pde4 inhibitors
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
WO2004005258A1 (en) 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors
SI1521733T1 (sl) 2002-07-08 2014-10-30 Pfizer Products Inc. Modulatorji glukokortikoidnega receptorja
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
TW200409746A (en) 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
AR040962A1 (es) * 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
CA2494650A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
WO2004018450A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-n-oxide-derivatives
HRP20050198A2 (hr) 2002-08-10 2006-04-30 Altana Pharma Ag Piperidin-piridazoni i ftalazoni kao inhibitori pde4
AU2003255376A1 (en) 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
RS20050117A (en) 2002-08-17 2007-06-04 Altana Pharma Ag., Novel benzonaphthyridines
CA2495597A1 (en) 2002-08-17 2004-03-04 Altana Pharma Ag Novel phenanthridines
US6858627B2 (en) 2002-08-21 2005-02-22 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
GB0219512D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
JP2006501236A (ja) 2002-08-23 2006-01-12 ランバクシー ラボラトリーズ リミテッド ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有３，６−二置換アザビシクロ（３．１．０）ヘキサン誘導体
AU2003273805B8 (en) 2002-08-29 2010-06-17 Takeda Gmbh 3-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
AU2003255493B8 (en) 2002-08-29 2009-03-26 Takeda Gmbh 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
PL375513A1 (en) 2002-08-29 2005-11-28 Boehringer Ingelheim Pharmaceuticals, Inc. 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
JP2006096662A (ja) 2002-09-18 2006-04-13 Sumitomo Pharmaceut Co Ltd 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
JP2004107299A (ja) 2002-09-20 2004-04-08 Japan Energy Corp 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤
JP4520309B2 (ja) 2002-09-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション 選択的糖質コルチコイド受容体調節剤としてのオクタヒドロ−２−Ｈ−ナフト［１，２−ｆ］インドール−４−カルボキサミド誘導体
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1556034B1 (en) 2002-10-11 2008-04-16 Pfizer Limited Indole derivatives as beta-2 agonists
DE60315492T2 (de) 2002-10-22 2008-04-24 Glaxo Group Ltd., Greenford Medizinisch verwendbare arylethanolamin verbindungen
PL376769A1 (pl) 2002-10-23 2006-01-09 Glenmark Pharmaceuticals Ltd. Nowe związki tricykliczne użyteczne w leczeniu chorób zapalnych i alergicznych, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające
CA2503588A1 (en) 2002-10-28 2004-05-06 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE10253426B4 (de) 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10261874A1 (de) 2002-12-20 2004-07-08 Schering Ag Nichtsteroidale Entzündungshemmer
RU2328499C2 (ru) 2003-01-09 2008-07-10 Астеллас Фарма Инк. Производные пирролопиридазина, фармацевтическая композиция, способ профилактики или лечения заболеваний, применение в качестве ингибитора фосфодиэстеразы iv, и/или продуцирования tnf
JP4606408B2 (ja) 2003-01-21 2011-01-05 メルク・シャープ・エンド・ドーム・コーポレイション 選択的グルココルチコイド受容体調節物質としての１７−カルバモイルオキシコルチゾル誘導体
TWI324150B (en) 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
PE20050211A1 (es) 2003-04-02 2005-04-27 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
EP1613315B1 (en) 2003-04-04 2009-01-21 Novartis AG Quinoline-2-one-derivatives for the treatment of airways diseases
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
MXPA05013059A (es) 2003-06-04 2006-03-02 Pfizer Derivados de 2-amino-piridina como agonistas del adrenoceptor beta-2.
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
JP2006527207A (ja) 2003-06-11 2006-11-30 メルク フロスト カナダ リミテツド ７−（１，３−チアゾール−２−イル）チオ−クマリン誘導体およびそれのロイコトリエン生合成阻害薬としての使用
TW200510298A (en) 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
WO2004111044A1 (en) 2003-06-17 2004-12-23 Glenmark Pharmaceuticals Ltd. Tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
JP2007524698A (ja) * 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト シクレソニドとグリコピロニウムとの組合せ物
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US20060239935A1 (en) * 2005-04-23 2006-10-26 Boehringer Ingelheim International Gmbh Compositions for inhalation
EP2778064A1 (en) 2013-03-14 2014-09-17 Airbus Operations GmbH Passenger services provisioning for a means of transport
PL3197429T3 (pl) 2014-09-25 2024-09-30 Boehringer Ingelheim Vetmedica Gmbh Leczenie skojarzone inhibitorami sglt2 i agonistami dopaminy do profilaktyki zaburzeń metabolicznych u zwierząt koniowatych

Also Published As

Publication number Publication date
NO334760B1 (no) 2014-05-19
GB0411056D0 (en) 2004-06-23
SG153836A1 (en) 2009-07-29
KR20130018429A (ko) 2013-02-21
BRPI0511327B8 (pt) 2021-05-25
DK1755590T3 (da) 2011-12-12
DK2228064T3 (da) 2020-03-16
LUC00155I2 (en, 2012) 2021-02-17
EP2228064A3 (en) 2011-11-02
WO2005110402A1 (en) 2005-11-24
EP2228064A2 (en) 2010-09-15
MXPA06013382A (es) 2007-03-23
HUS2000014I1 (hu) 2020-07-28
US20130237564A1 (en) 2013-09-12
SI2228064T1 (sl) 2020-04-30
ES2370647T3 (es) 2011-12-21
NO2014020I2 (en, 2012) 2014-08-07
LTPA2014015I1 (lt) 2014-04-25
NZ550369A (en) 2009-11-27
JP2007538036A (ja) 2007-12-27
AU2005244439B2 (en) 2009-07-30
EP1755590B1 (en) 2011-08-24
CN1953745A (zh) 2007-04-25
CY1122863T1 (el) 2020-11-25
EP3603634A1 (en) 2020-02-05
MA28598B1 (fr) 2007-05-02
JP5567252B2 (ja) 2014-08-06
TNSN06377A1 (en) 2008-02-22
US20180071276A1 (en) 2018-03-15
US20160101097A1 (en) 2016-04-14
HUS1400013I1 (hu) 2016-11-28
PT2228064T (pt) 2020-08-25
CA2563302C (en) 2012-08-28
FR20C1018I1 (fr) 2020-07-10
PL1755590T3 (pl) 2012-01-31
CA2563302A1 (en) 2005-11-24
EP3603634B1 (en) 2025-02-12
KR101360556B9 (ko) 2022-08-12
EP1755590A1 (en) 2007-02-28
LT2228064T (lt) 2020-03-25
KR20070011519A (ko) 2007-01-24
PT1755590E (pt) 2011-10-27
CY1112086T1 (el) 2015-11-04
NO20065787L (no) 2006-12-14
LTC1755590I2 (lt) 2018-05-10
BRPI0511327B1 (pt) 2019-08-06
LTC2228064I2 (lt) 2022-05-10
RU2006144810A (ru) 2008-06-27
LUC00155I1 (en, 2012) 2020-05-27
KR101360556B1 (ko) 2014-02-21
CY2020013I1 (el) 2020-11-25
SI1755590T1 (sl) 2011-12-30
ES2775979T3 (es) 2020-07-28
ECSP066950A (es) 2006-12-20
NO2014020I1 (no) 2014-08-07
US20190282561A1 (en) 2019-09-19
HK1105579A1 (en) 2008-02-22
AU2005244439A1 (en) 2005-11-24
EP2228064B1 (en) 2019-12-11
AU2005244439C1 (en) 2014-09-11
IL179013A0 (en) 2007-05-15
CY2020013I2 (el) 2020-11-25
SE1755590T5 (en, 2012) 2015-01-20
JP2012236833A (ja) 2012-12-06
CY2014014I1 (el) 2015-11-04
PL2228064T3 (pl) 2020-06-01
BRPI0511327A (pt) 2007-12-04
HUE048936T2 (hu) 2020-09-28
ATE521348T1 (de) 2011-09-15
LTPA2020509I1 (lt) 2020-07-10
FR20C1018I2 (fr) 2023-11-03
IL179013A (en) 2012-02-29
US20210236478A1 (en) 2021-08-05
RU2388465C2 (ru) 2010-05-10
US20080267886A1 (en) 2008-10-30
ZA200608123B (en) 2008-07-30

Similar Documents

Publication Publication Date Title
BE2024C508I2 (en, 2012)
BE2022C549I2 (en, 2012)
BE2023C542I2 (en, 2012)
BE2021C001I2 (en, 2012)
BE2020C513I2 (en, 2012)
BE2020C517I2 (en, 2012)
BE2019C540I2 (en, 2012)
BE2019C523I2 (en, 2012)
BE2019C506I2 (en, 2012)
BE2019C548I2 (en, 2012)
BE2018C045I2 (en, 2012)
BE2017C063I2 (en, 2012)
BE2020C525I2 (en, 2012)
BE2017C027I2 (en, 2012)
BE2017C023I2 (en, 2012)
BE2017C002I2 (en, 2012)
BE2016C067I2 (en, 2012)
BE2016C014I2 (en, 2012)
BE2015C041I2 (en, 2012)
BE2015C038I2 (en, 2012)
BE2015C014I2 (en, 2012)
BE2015C015I2 (en, 2012)
BE2015C066I2 (en, 2012)
BE2014C071I2 (en, 2012)
BE2014C064I2 (en, 2012)